SG10201609318UA - Cyclodextrin complexation methods for formulating peptide proteasome inhibitors - Google Patents

Cyclodextrin complexation methods for formulating peptide proteasome inhibitors

Info

Publication number
SG10201609318UA
SG10201609318UA SG10201609318UA SG10201609318UA SG10201609318UA SG 10201609318U A SG10201609318U A SG 10201609318UA SG 10201609318U A SG10201609318U A SG 10201609318UA SG 10201609318U A SG10201609318U A SG 10201609318UA SG 10201609318U A SG10201609318U A SG 10201609318UA
Authority
SG
Singapore
Prior art keywords
proteasome inhibitors
peptide proteasome
cyclodextrin complexation
complexation methods
formulating peptide
Prior art date
Application number
SG10201609318UA
Other languages
English (en)
Inventor
Evan Lewis
Peter Shwonek
Sean Dalziel
Mouhannad Jumaa
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201609318U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of SG10201609318UA publication Critical patent/SG10201609318UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
SG10201609318UA 2012-05-08 2013-05-08 Cyclodextrin complexation methods for formulating peptide proteasome inhibitors SG10201609318UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08
US201361777475P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
SG10201609318UA true SG10201609318UA (en) 2016-12-29

Family

ID=48326170

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407337QA SG11201407337QA (en) 2012-05-08 2013-05-08 Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
SG10201609318UA SG10201609318UA (en) 2012-05-08 2013-05-08 Cyclodextrin complexation methods for formulating peptide proteasome inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407337QA SG11201407337QA (en) 2012-05-08 2013-05-08 Cyclodextrin complexation methods for formulating peptide proteasome inhibitors

Country Status (14)

Country Link
US (1) US10159746B2 (zh)
EP (1) EP2662094B1 (zh)
JP (1) JP6410264B2 (zh)
KR (4) KR20190137963A (zh)
CN (2) CN104411334A (zh)
AU (2) AU2013259573B2 (zh)
CA (1) CA2873044C (zh)
CL (1) CL2014003055A1 (zh)
EA (1) EA033614B1 (zh)
HK (2) HK1207827A1 (zh)
IL (1) IL235553B (zh)
MX (2) MX364393B (zh)
SG (2) SG11201407337QA (zh)
WO (1) WO2013169897A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016000568A (es) 2013-07-19 2016-08-01 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
US10836756B2 (en) 2016-06-29 2020-11-17 Kezar Life Sciences Crystalline salts of peptide epoxyketone immunoproteasome inhibitor
MX2018016386A (es) 2016-06-29 2019-09-09 Kezar Life Sciences Proceso de preparacion de un inhibidor de inmunoproteasoma de peptido epoxicetona, y precursores del mismo.
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
MD3548091T2 (ro) * 2016-11-29 2022-03-31 Oculis SA Prepararea complexelor solide de ciclodextrină pentru livrarea ingredientelor farmaceutice active oftalmice
CA3062308A1 (en) * 2017-05-03 2018-11-08 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
CN110882221B (zh) * 2019-11-29 2021-06-29 健进制药有限公司 一种注射用卡非佐米冻干制剂的生产工艺
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
ATE323110T1 (de) 1997-07-01 2006-04-15 Pfizer Prod Inc Verfahren zur herstellung von einem cyclodextrin
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
ES2272558T3 (es) 2000-10-12 2007-05-01 Viromics Gmbh Inhibidores del proteasoma para el tratamiento de infecciones causadas por virus de la hepatitis.
EP1729724A4 (en) * 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
ATE494298T1 (de) * 2004-04-15 2011-01-15 Proteolix Inc Verbindungen zur proteasomenzymhemmung
ATE499109T1 (de) * 2004-12-07 2011-03-15 Proteolix Inc Zusammensetzung zur proteasomhemmung
JP2009516001A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤とシクロデキストリンとを含む組成物
MX2010003732A (es) * 2007-10-04 2010-08-09 Onyx Therapeutics Inc Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido.
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
MX2011004225A (es) 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
KR20160033795A (ko) 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
EA033614B1 (ru) 2019-11-11
HK1207827A1 (zh) 2016-02-12
CA2873044C (en) 2021-01-26
IL235553A0 (en) 2015-01-29
KR20220088949A (ko) 2022-06-28
CL2014003055A1 (es) 2015-02-13
JP6410264B2 (ja) 2018-10-24
MX2014013552A (es) 2015-05-08
MX2019004845A (es) 2021-03-31
KR20150008165A (ko) 2015-01-21
AU2013259573B2 (en) 2018-02-15
US20150111838A1 (en) 2015-04-23
US10159746B2 (en) 2018-12-25
EP2662094B1 (en) 2024-04-17
KR20190137963A (ko) 2019-12-11
JP2015516430A (ja) 2015-06-11
KR20200130748A (ko) 2020-11-19
WO2013169897A1 (en) 2013-11-14
CN104411334A (zh) 2015-03-11
CN107693772A (zh) 2018-02-16
AU2013259573A1 (en) 2014-11-27
EP2662094A1 (en) 2013-11-13
AU2018200444B2 (en) 2019-10-31
AU2018200444A1 (en) 2018-02-08
EA201491994A1 (ru) 2015-04-30
HK1250927A1 (zh) 2019-01-18
KR102054329B1 (ko) 2019-12-10
CA2873044A1 (en) 2013-11-14
SG11201407337QA (en) 2014-12-30
MX364393B (es) 2019-04-24
IL235553B (en) 2018-04-30

Similar Documents

Publication Publication Date Title
ZA201207384B (en) Cylodextrin complexation methods for furmulating peptide proteasome inhibitors
HK1250927A1 (zh) 用於配製肽蛋白酶體抑制劑的環糊精絡合法
EP2755192A4 (en) VISUALALLY DISTANCE DRIVING DETECTION DEVICE
EP2877458A4 (en) CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER
EP2877457A4 (en) CYSTATHIONINE -LYASE INHIBITORS (CSE)
EP2685271A4 (en) MAGNETIC DETECTION DEVICE
EP2725338A4 (en) TIRE TEST DEVICE
EP2785183A4 (en) TRIAZOLOPYRIDINONE PDE10 INHIBITORS
EP2782271A4 (en) VECTORIAL SIGNAL ANALYZER
EP2715527A4 (en) OPERATIONS REVIEW POINTS
GB2492805B (en) Apparatus for measuring an article
GB2494284B (en) Detection aid device
EP2772636A4 (en) DEVICE FOR DETECTING CATALYST DEGRADATION
ZA201300859B (en) Sweep design for seismic sources
EP2661633A4 (en) PROOF OF PROTEOLYSIS
GB2490789B (en) A device for withdrawing objects from a narrow space
HK1209422A1 (zh) 抑制劑
EP2687687A4 (en) DEVICE FOR TREATING PARTICULATE MATTER
GB2495391B (en) Detection device
PL2780897T3 (pl) Urządzenie do przenoszenia monet
EP2716556A4 (en) VACUUM PACKAGING DEVICE
EP2763108A4 (en) MONEY PROCESSING DEVICE
EP2690606A4 (en) STATEMENT PROCESSING DEVICE
EP2778103A4 (en) DEVICE FOR TREATING CONTAINERS
GB201115061D0 (en) Tobacco reclaim device